Skip to content

Scientific Advisory Board

Nathan B. Fountain, M.D.

Chair, Scientific Advisory Board

Director, F.E. Dreifuss Comprehensive Epilepsy Program & Director, EEG and Epilepsy Fellowships University of Virginia School of Medicine, Charlottesville, Virginia

Emilio Perucca, Ph.D., M.D.

Member, Scientific Advisory Board

Clinical Professor, Department of Medicine (Austin Health), The University of Melbourne, Melbourne, Australia Adjunct Professor, Department of Neuroscience, Monash University, Melbourne, Australia

Enrique J. Carrazana, M.D., F.A.E.S.

Member, Scientific Advisory Board

Chief Medical Officer, Neurelis, Inc. Director, Board of Directors, American Society for Experimental Neurotherapeutics (ASENT), Hawaii Biotech, Inc., CND Life Sciences, & Apex Labs

Jeffrey Buchhalter, M.D., Ph.D.

Member, Scientific Advisory Board

Adjunct Professor of Pediatrics at the University of Calgary and former director of the pediatric epilepsy programs at Alberta Children’s Hospital, Phoenix Children’s Hospital and the Mayo Clinic, Rochester

Judy Ashworth, B.A., M.D.

Member, Scientific Advisory Board

Vice President, Rx Strategic Services & Chief Medical Officer, Pinney Associates, Inc. Chief Medical Officer, Harm Reduction Therapeutics.

Jack E. Henningfield, Ph.D.

Member, Scientific Advisory Board

Vice President, Research, Health Policy, and Abuse Liability, Pinney & Associates. Professor, Adjunct, Behavioral Biology at The Johns Hopkins University.

Michael Shannon, M.A., M.Sc., M.D.

Member, Scientific Advisory Board

Former Deputy Surgeon General of Canada and Director General for the Laboratory Centre for Disease Control.

Robert Laprairie, Ph.D

Member, Scientific Advisory Board

Associate Professor and GlaxoSmithKline-Canadian Institutes of Health Research Chair in Drug Discovery and Development College of Pharmacy and Nutrition, University of Saskatchewan Adjunct Professor, Department of Pharmacology, Dalhousie University

Invest in Shackelford

Shackelford Pharma’s Regulation A Financing is now open. Investors are required to fill out the form below to begin the investment process.

Please check your JUNK/SPAM email folder if your invitation email from Dealmaker/Shackelford does not arrive in your inbox.

Invest Shackelford